Virtual Library

Start Your Search

SERAFIN Morales



Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 2
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      15P - TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor (ID 377)

      12:30 - 13:00  |  Author(s): SERAFIN Morales

      • Abstract
      • Slides

      Background

      Patients with thyroid transcription factor 1 (TTF1) negative lung adenocarcinoma (ADC) have been reported to have a worse prognosis and to lack epidermal growth factor receptor (EGFR) mutations. The aim of this study was to analyse the prognostic significance of TTFI status in a series of tumor samples from patients with clinically confirmed lung adenocarcinoma.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      A real-world data study of TTF1-negative ADC was performed in all lung cancer patients diagnosed in the University Hospital of Lleida from January 2011 to December 2016, using TTF1 clone 8G7G3/1(DAKO®). Each patient’s clinical history, pathology specimens and molecular results were noted. The control group consisted of 231 patients with TTF1 positive lung ADC .

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      Three hundred and thirty four (334) patients with ADC were identified; TTF1 results were available in 258 (77,2%) cases. Of these, 27 (10,4%) patients were identified with TTF1-negative ADC (74% males). The median age of these patients was 66 years and their smoking history was as follows: 55,5% former smoker, 29,6% ex smokers and 14,8% never smokers. The clinical stages were as follows: stage I or II (n = 3 [11%]), stage III (n = 4 [14,8%]) and stage IV (n = 20 [74%]). Patients’ mean survival was 7,6 vs 24,4 months in ADC TTF1-negative patients versus TTF1-postive patients (P = 0,00001). When compared with the control group, TTF1-negative patients had shorter overall survival (P = 0,00001), regardless of whether patients were treated with radical or palliative intent: 34,4 vs 10, months P = 0,00001 (radical treatment) and 14,6 vs 6,7 months P = 0,007 (palliative intent). EGFR mutations were less frequent (P = 0,046) in TTF-negative tumors compared to the control group (5,5% vs 25,3%).

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      Patients with TTF1-negative NSCLC ADC have worse overall survival, regardless of treatment intention, and a lower frequency of EGFR mutations.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      80P - High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC) (ID 543)

      12:30 - 13:00  |  Author(s): SERAFIN Morales

      • Abstract
      • Slides

      Background

      Patients with high blood platelets levels (BPL) have been reported to attenuate the efficacy of platinum-based chemotherapy and to have a worse prognosis when treated with surgery and postoperative adjuvant chemotherapy. This study describes a series of sample tumors from patients with clinically confirmed lung cancer.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      In all non-small cell lung cancer (NSCLC) patients diagnosed in the University Hospital of Lleida from January 2011 to December 2016, a real world data study of blood platelets levels (BPL) was performed. Each patient’s clinical history, pathology specimens and molecular results were noted. Four hundred and forty-five patients with low BPL formed the control group.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      The blood platelet levels (BPL) was analyzed in seven hundred and seventy-five (775) patients with an average of 290 mcL (24 - 995). In 330 patients (42%) a platelet level greater than 290 mcL was observed (22,1% females). The media age was 67 years. The smoking history was as follows: 57,2% former, 31,5% ex smokers and 11,2 never smokers. The clinical stages and histology were as follows: stage I and II: 17%, stage III: 30% and stage IV 53%; 43% of patients had adenocarcinoma histology, 36% squamous and 21% other. In patients treated with radical intention (surgery or chemotherapy plus radiotherapy) the median overall survival was 49 vs 36 months in patients with BPL ≥ 290 mcL (P = 0,00001), when they were compared with the control group, patients with high BPL (≥ 290 mcL) had overall shorter survival (P = 0,00001), regardless of histology, age or smoking history.

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      Patients treated with radical intention and high BPL (≥ 290 mcL), have worse overall survival, regardless of histology, age or smoking history.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.